Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (vol 398, pg 1344, 2021)

被引：0
|
作者：
Felip, Enriqueta
Altorki, Nasser
Zhou, Caicun
Csoszi, Tibor
Vynnychenko, Ihor
Goloborodko, Oleksandr
Luft, Alexander
Akopov, Andrey
Martinez-Marti, Alex
Kenmotsu, Hirotsugu
Chen, Yuh-Min
Chella, Antonio
Sugawara, Shunichi
Voong, David
Wu, Fan
Yi, Jing
Deng, Yu
McCleland, Mark
Bennett, Elizabeth
Gitlitz, Barbara
Wakelee, Heather
机构：
来源：
LANCET | 2021年 / 398卷 / 10312期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1686 / 1686
页数：1
相关论文
共 50 条
  • [31] Randomized Phase Ill Trial of Adjuvant Chemotherapy With Gemcitabine Compared With Oral Tegafur-uracil (UFT) in Resected, Stage IB-IIIa Non-small Cell Lung Cancer (WJTOG 0101)
    Mitsudomi, T.
    Tada, H.
    Ichinose, Y.
    Yokoi, K.
    Katakami, N.
    Oda, M.
    Negoro, S.
    Chiba, Y.
    Nakagawa, K.
    Nakanishi, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S594 - S594
  • [32] Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
    Shu, Catherine A.
    Gainor, Justin F.
    Awad, Mark M.
    Chiuzan, Codruta
    Grigg, Claud M.
    Pabani, Aliyah
    Garofano, Robert F.
    Stoopler, Mark B.
    Cheng, Simon K.
    White, Abby
    Lanuti, Michael
    D'Ovidio, Frank
    Bacchetta, Matthew
    Sonett, Joshua R.
    Saqi, Anjali
    Rizvi, Naiyer A.
    LANCET ONCOLOGY, 2020, 21 (06): : 786 - 795
  • [33] Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
    Bellmunt, Joaquim
    Hussain, Maha
    Gschwend, Jurgen E.
    Albers, Peter
    Oudard, Stephane
    Castellano, Daniel
    Daneshmand, Siamak
    Nishiyama, Hiroyuki
    Majchrowicz, Martin
    Degaonkar, Viraj
    Shi, Yi
    Mariathasan, Sanjeev
    Grivas, Petros
    Drakaki, Alexandra
    O'Donnell, Peter H.
    Rosenberg, Jonathan E.
    Geynisman, Daniel M.
    Petrylak, Daniel P.
    Hoffman-Censits, Jean
    Bedke, Jens
    Kalebasty, Arash Rezazadeh
    Zakharia, Yousef
    van der Heijden, Michiel S.
    Sternberg, Cora N.
    Davarpanah, Nicole N.
    Powles, Thomas
    LANCET ONCOLOGY, 2021, 22 (04): : 525 - 537
  • [34] Adjuvant chemotherapy in completely resected non-small-cell lung cancer (vol 23, pg 3270, 2005)
    Pisters
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5851 - 5851
  • [35] Adjuvant chemotherapy in completely resected non-small-cell lung cancer (vol 23, pg 3270, 2005)
    Pisters
    Le Chevalier
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2238 - 2238
  • [36] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    Fehrenbacher, Louis
    Spira, Alexander
    Ballinger, Marcus
    Kowanetz, Marcin
    Vansteenkiste, Johan
    Mazieres, Julien
    Park, Keunchil
    Smith, David
    Artal-Cortes, Angel
    Lewanski, Conrad
    Braiteh, Fadi
    Waterkamp, Daniel
    He, Pei
    Zou, Wei
    Chen, Daniel S.
    Yi, Jing
    Sandler, Alan
    Rittmeyer, Achim
    LANCET, 2016, 387 (10030): : 1837 - 1846
  • [37] Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients
    Li, Xiao
    Zhang, Chao
    Sun, Zewen
    Yang, Fan
    Xiao, Rongxin
    Sui, Xizhao
    Jiang, Guanchao
    Zhong, Wenzhao
    Wang, Jun
    LUNG CANCER, 2019, 133 : 75 - 82
  • [38] Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
    Reck, Martin
    Mok, Tony S. K.
    Nishio, Makoto
    Jotte, Robert M.
    Cappuzzo, Federico
    Orlandi, Francisco
    Stroyakovskiy, Daniil
    Nogami, Naoyuki
    Rodriguez-Abreu, Delvys
    Moro-Sibilot, Denis
    Thomas, Christian A.
    Barlesi, Fabrice
    Finley, Gene
    Lee, Anthony
    Coleman, Shelley
    Deng, Yu
    Kowanetz, Marcin
    Shankar, Geetha
    Lin, Wei
    Socinski, Mark A.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (05): : 387 - 401
  • [39] Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
    K Nakagawa
    H Tada
    A Akashi
    T Yasumitsu
    K Iuchi
    T Taki
    K Kodama
    British Journal of Cancer, 2006, 95 : 817 - 821
  • [40] International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer (vol 33, pg 57, 2022)
    Novello, S.
    Torri, V.
    Grohe, C.
    Kurz, S.
    Serke, M.
    Wehler, T.
    Meyer, A.
    Ladage, D.
    Geissler, M.
    Colantonio, I.
    Cauchi, C.
    Stoelben, E.
    Ceribelli, A.
    Kropf-Sanchen, C.
    Valmadre, G.
    Borra, G.
    Schena, M.
    Morabito, A.
    Santo, A.
    Gregorc, V.
    Chiari, R.
    Reck, M.
    Schmid-Bindert, G.
    Folprecht, G.
    Griesinger, F.
    Follador, A.
    Pedrazzoli, P.
    Bearz, A.
    Caffo, O.
    Dickgreber, N. J.
    Irtelli, L.
    Wiest, G.
    Monica, V.
    Porcu, L.
    Manegold, C.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2022, 33 (04) : 454 - 454
12345